Avalo Therapeutics AVTX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$84.74M-8.3% | -$78.26M+21.6% | -$99.88M-116% | -$46.22M-163% | $73.01M+308% | ||
| $226K-34.3% | $344K-13.1% | $396K+6.7% | $371K+37.4% | $270K+59.8% | ||
| $13.96M+2.5% | $13.62M+13.3% | $12.02M+12.2% | $10.71M+26.5% | $8.46M+44.6% | ||
| -$59.69M-16.0% | -$51.46M+1.5% | -$52.26M-10.2% | -$47.42M+9.4% | -$52.31M-6.6% | ||
| -$58.62M+30.3% | -$84.12M— | —— | —— | —— | ||
| $15.99M+9.6% | $14.59M-82.1% | $81.61M— | —— | —— | ||
| -$99.92M+15.7% | -$118.59M-117% | -$54.77M— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Avalo Therapeutics generate?
- Avalo Therapeutics (AVTX) generated -$59.7M in operating cash flow over the trailing twelve months.
- Where does Avalo Therapeutics's cash flow data come from?
- Every line is extracted from Avalo Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
